Japan’s cost-effectiveness assessment (CEA) panel has approved a revised handling policy for the CEA system for FY2026, with the health…
HOME > REGULATORY
REGULATORY
- Govt Panel to Draw Up New AMR Action Plan for 2021 and Beyond
November 29, 2019
- Amended PMD Law Set for 3-Step Enforcement, 1st Execution Eyed Next Autumn
November 28, 2019
- LDP to Forge Lawmakers’ League Aimed to Reinstate HPV Vaccine Recommendation
November 27, 2019
- “All-Generation” Panel Cites Coverage of OTC-Like Drugs as Policy Issue
November 27, 2019
- Japan Enacts Amended Pharmaceuticals and Medical Devices Law
November 27, 2019
- Japan’s First Biosimilars of Avastin, Nesp, Forteo Receive Listing
November 27, 2019
- MOF Panel Leery of Pricey Drugs for Huge Patient Population: FY2020 Budget Recommendation
November 26, 2019
- MHLW Panel OKs Bayer’s Xtandi Rival, AbbVie’s JAK Inhibitor; 2 More Keytruda Usages Now in Line for Approval
November 26, 2019
- MHLW Panel Members Call for Need to “at Least Discuss” Whether to Resume Actively Recommending HPV Vaccines
November 26, 2019
- Plaintiffs of HPV Vaccine Suits Prod JMA to Hear Stories of Victims
November 26, 2019
- MHLW Floats 2 Rules to Address Unreasonable Price Rises for Listed Generics
November 26, 2019
- Xolair’s Pollen Allergy Nod Delayed as Novartis Says It Needs More Time to Prepare for Launch
November 25, 2019
- Chuikyo Members Remain Divided over Timing of Comparator PMP Removal
November 25, 2019
- MHLW Wants to Subject Innovative Add’l Use to PMP, but No Price Raise
November 25, 2019
- MHLW Wants to Ease Unfairness Concerns by Adding New Innovation Gauge to PMP Company Criteria
November 25, 2019
- Industry Urges Careful Approach to Creating Special Rule for Indication Change Re-Pricing: Chuikyo
November 25, 2019
- Japan Approves Add’l Indications for Taltz, Lucentis and More
November 25, 2019
- No Change to Essential Drug Rule in 2020 Reform: MHLW
November 25, 2019
- MHLW Proposes Earlier Price Cuts for Off-Patent Drugs with 80%-Plus Gx Rates, but Chuikyo Questions 2-Year Grace Period
November 25, 2019
- MHLW Proposes Continued Discussions for Cell & Gene Therapy Pricing
November 25, 2019
ページ
Japan’s health and finance ministers agreed late last year to go ahead with an “off-year” drug price revision in FY2027,…
The Japanese healthcare sector is experiencing rapid growth, demanding a highly skilled and diverse workforce. However, finding and attracting the best talent in this competitive market presents significant challenges.Enter AI. With the rise of AI-powered tools, healthcare organizations can revolutionize…
Japan’s Central Social Insurance Medical Council (Chuikyo) on November 5 approved the reimbursement listing for a slate of new medicines,…
The Japanese government on March 7 announced new NHI prices to be applied in the FY2025 drug price revision, revealing…
The Japanese government approved a bill to amend the Pharmaceuticals and Medical Devices (PMD) Act at its Cabinet meeting on…
Japan’s health ministry doled out regulatory approvals for a throng of new medicines on December 27 including Eli Lilly’s obesity…
Japan’s all-important reimbursement policy panel on December 20 approved an outline of drug pricing reforms for FY2024, which enshrines a…